Thu, Jan 29, 2015, 3:35 PM EST - U.S. Markets close in 25 mins.


% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • yougottasayyes yougottasayyes Dec 5, 2012 12:54 AM Flag

    SVR 4 IS NOT! SVR 12!! IS NOT! SVR 24!!

    True... EOT does not translate to SVR4... and SVR4 is still too early but starts to be a good indicator. SVR12, however... that you may want to hang your hat on these days. Here is a bit of info on drug pharmacokinetics. Peg has a pretty long half-life (not to mention ribavirin...why do you think the ribavirin label tells you to practice safe you-know-what for a long time AFTER you finish taking the drug?)... anyway you need to get to SVR12 with Peg/Riba just to see if there will be a lot of relapse due to this half-life (I didn't make this up... there is good data in the public domain from companies and the FDA to show this). If you are giving oral therapies with a short half-life, the drug pressure is gone rapidly. HCV also grows very fast (just ask a liver transplant patient) once the drug pressure is removed. I would have strong doubts you will see much relapse if any after SVR12. Probably you will see some patients in the study lost to follow-up between 12 and 24 (that is a long time to expect someone to come back for a blood draw) that may be counted conservatively as a "failure"... but that is really just a failure to obtain a blood draw!

    I always find it so funny when people try to say things on these boards to get folks all crazy. I don't even have holding in these companies... I just know the science and it annoys me when people start shouting that the earth is flat and herbs and berries will cure you of all your woes.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
114.02-7.24(-5.97%)3:35 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.